East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin for Oral Solution USP, 500 mg . Aurobindo Pharma’s Vigabatrin for Oral Solution USP, 500 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Sabril for Oral Solution of Lundbeck Pharmaceuticals, LLC.

Vigabatrin for Oral Solution are indicated as:

• Adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures.
• Monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age.